<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99319">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02126358</url>
  </required_header>
  <id_info>
    <org_study_id>LG-GSCL002</org_study_id>
    <nct_id>NCT02126358</nct_id>
  </id_info>
  <brief_title>Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3</brief_title>
  <official_title>A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of the Fix-dose Combination Therapy With Gemigliptin 50mg and Rosuvastatin 20mg With Type 2 Diabetes and Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of the fix-dose combination therapy with Gemigliptin
      50mg and Rosuvastatin 20mg with type 2 diabetes and dyslipidemia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>HbA1c change</measure>
    <time_frame>Baseline(Day 0) to Treatment (last visit, w24)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL-C change rate</measure>
    <time_frame>Baseline(Day 0) to Treatment (last visit, w24)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Baseline(Day 0) to Treatment (last visit, w24)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>(Gemigliptin/Rosuvastatin FDC vs. Gemigliptin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C change rate</measure>
    <time_frame>Baseline(Day 0) to Treatment (last visit, w24)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>(Gemigliptin/Rosuvastatin FDC vs. Rosuvastatin)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Gemigliptin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>only Gemiglitpin (Gemiglitpin/Rosuvastatin FDC:Placebo , Rosuvastatin :Placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>only Rosuvastatin (Gemiglitpin/Rosuvastatin FDC:Placebo , gemigliptin :Placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemigliptin &amp; Rosuvastatin (Gemiglitpin only:Placebo ,Rosuvastatin only:Placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin and/or Rosuvastatin</intervention_name>
    <arm_group_label>Gemigliptin</arm_group_label>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_label>FDC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes Mellitus with Dyslipidemia

          -  Adults who are at least 19 years old

        Exclusion Criteria:

          -  Patients with type 1 diabetes, diabetic ketoacidosis, diabetic coma and pre-coma

          -  Patients with gestational diabetes or secondary diabetes

          -  Patients with NYHA Class III, IV congestive heart failure or arrhythmias requiring
             treatment

          -  Patients with thyroid gland dysfunction deviating from the normal TSH range

          -  Patients with pituitary insufficiency or adrenal insufficiency
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>YoungKyoung Lee, study leader</last_name>
    <phone>+82-2-6924-3117</phone>
    <email>yklee@lgls.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SungKyung Kim, Project Manager</last_name>
      <phone>+82-2-2010-4577</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>March 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosuvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
